An observational study in Breast Cancer, sponsored by Hellenic Cooperative Oncology Group. Active, not recruiting at 1 site in Greece. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Hellenic Cooperative Oncology Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group — 3 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Hellenic Cooperative Oncology Group.
Among the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, this one is the 6th largest by enrollment of the 14 observational ones that give a count, is one of 2 that started in 2013, is one of 14 observational ones, and was the 7th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →3 of the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group are open now, in 1 country. Recruiting first, the newest first:
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+ · Women only
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 500 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 82 across the 3 interventional studies, 423 across the 14 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hellenic Cooperative Oncology Group is the lead sponsor of 62 studies on the registry; 6 are open to participants now.
2 of the studies in Breast Neoplasms by Hellenic Cooperative Oncology Group that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04985058Hellenic Cooperative Oncology GroupReal-world Data in Patients With Breast Cancer Treated With Abemaciclib | 2026-11-30 |
| NCT07899463Hellenic Cooperative Oncology GroupESR1 Mutations in Metastatic Hormone Receptor-Positive Breast Cancer in the Greek Population | 2027-05-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The present study is a transnational study in patients with high risk recurrent breast cancer who receive adjuvant chemotherapy with epirubicin and cyclophosphamide followed by docetaxel or paclitaxel.
This will be a retrospective analysis of patients with histologically confirmed triple-negative or HER2+ operable breast cancer (with high risk of recurrence) who are treated at Hellenic Cooperative Oncology Group (HeCOG)- affiliated departments of oncology. Patients who participate are 18 years or older, women of any menopausal status with triple-negative or HER2+ breast cancer who receive epirubicin and cyclophosphamide every two weeks followed by docetaxel every three weeks or weekly paclitaxel. Patients with HER2-positive tumors are treated with trastuzumab, initiated concurrently with the first cycle of docetaxel, for 52 weeks. Pertuzumab may be combined with trastuzumab only in patients with node-positive disease.Patients can be treated with hormone therapy and/or radiotherapy. The investigation of the potential biomarkers will be performed using in situ methods in Formalin fixed paraffin embedded (FFPE) tumor sections. More specific will be investigated the expression of estrogen and progesterone receptors, the expression of SPARC proteins, special cellular activation and metastasis systems and other important pathways in cell life and reproduction.
Statistical analysis: The primary endpoint of the study will be the progression-free survival (PFS), defined as the time from treatment initiation to either the first documented disease progression or death from any cause. Second primary endpoint will be the overall survival (OS), defined as the time from treatment initiation to patient's death or last contact. Survival curves will be estimated using the Kaplan-Meier method and compared across groups with the log-rank test. The associations between the clinicopathological factors to be examined and the mortality rate will be evaluated with hazard ratios estimated with Cox proportional hazards model. The statistical analyses will be completed using the SAS software (SAS for Windows, version 9.3, SAS Institute Inc., Cary, NC).
This is a retrospective analysis of patients with histologically confirmed HER2- positive breast adenocarcinoma,triple-negative breast cancer with high risk of recurrence.
Patients have been treated in Hellenic Cooperative Oncology Group (HeCOG)- affiliated departments of oncology.
Inclusion Criteria:
Exclusion Criteria: -
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with histologically confirmed triple-negative breast cancer. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
Patients with histologically confirmed HER2+ breast adenocarcinoma with high risk of recurrence. Patients had been treated in Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology.
Progression free survival
Time frame: From treatment initiation to the first documented disease progression, up to 5 years
Overall survival
Time frame: from thee date of treatment initiation until death from any cause or date of last contact whichever occurred first, assessed up to 5 years
Plan to share: No
Ran from Apr 2013 to primary completion in Jul 2026, 158 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Dec 2020 → Jul 2026 and completion Sep 2023 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hellenic Cooperative Oncology Group